Aura Biosciences (AURA) investor relations material

Company overview and business model

• Clinical-stage biotechnology firm focused on precision therapies for solid tumors, aiming to preserve organ function.

• Lead candidate, bel-sar, is in late-stage clinical development for early choroidal melanoma and other ocular oncology indications.

• Seeks to address unmet needs in ocular cancers where current treatments are highly invasive and often result in vision loss.

• Incorporated in Delaware in 2009, listed on Nasdaq under the symbol "AURA."

• Qualifies as an emerging growth and smaller reporting company, utilizing reduced disclosure requirements.

Financial performance and metrics

• As of June 30, 2026, net tangible book value was $2.90 per share, with $300.3 million in net tangible book value.

• Offering could increase net tangible book value to $3.82 per share, with immediate dilution of $3.88 per share to new investors at an assumed $7.70 per share offering price.

• 103,480,053 shares of common stock outstanding as of June 30, 2026.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including R&D, clinical development, potential acquisitions or licensing, technology expansion, working capital, and capital expenditures.

• Management retains broad discretion over allocation; proceeds may be temporarily invested in short-term, investment-grade instruments or held as cash.